Compare ZETA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZETA | PRAX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.1B |
| IPO Year | 2021 | 2020 |
| Metric | ZETA | PRAX |
|---|---|---|
| Price | $31.02 | $285.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | $38.29 | ★ $650.00 |
| AVG Volume (30 Days) | ★ 4.9M | 468.2K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,304,668,000.00 | N/A |
| Revenue This Year | $39.47 | N/A |
| Revenue Next Year | $16.12 | $41,442.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.72 | N/A |
| 52 Week Low | $14.37 | $154.46 |
| 52 Week High | $35.75 | $392.70 |
| Indicator | ZETA | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 53.91 |
| Support Level | $30.24 | $284.55 |
| Resistance Level | $32.41 | $347.63 |
| Average True Range (ATR) | 1.70 | 12.62 |
| MACD | -0.30 | 6.37 |
| Stochastic Oscillator | 12.92 | 90.29 |
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing. The company operates in U.S, where it generates maximum revenue and Internationally as well.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.